Lee N. Newcomer, MD, of the UnitedHealth Group, gives his perspective on how to assess quality in the age of precision medicine.
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
Sandra L. Wong, MD, of the Dartmouth-Hitchcock Medical Center, summarizes three abstracts for which she was the discussant. The topics were rates of surgical site infections, an online resource for hospital cancer surgery volumes, and barriers to oncology appointments at comprehensive cancer centers. (Abstracts 171, 172, 55)
Randall F. Holcombe, MD, of the Icahn Mount Sinai School of Medicine, discusses the challenges of delivering quality care in an academic setting at a large hospital.
Steven Shak, MD, of Genomic Health, discusses mortality among patients with early-stage hormone receptor–positive invasive breast cancer in the SEER database who were treated based on the 21-gene Recurrence Score results (Abstract 176).
